{"schema_version":"secwatch.filing_event.v1","accession":"0000805928-24-000005","form_type":"8-K","ticker":"AXGN","cik":"0000805928","company_name":"Axogen, Inc.","filed_at":"2024-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.966840+00:00","generated_at":"2026-06-07T04:23:53.346060+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Axogen reports preliminary Q4 revenue $42.7M (+18% YoY); CEO Karen Zaderej to retire by Jan 2025","bullets":["Q4 revenue $42.7M (+18% YoY); FY2023 revenue $158.8M (+15% YoY) at high end of $154-159M guidance.","Gross margin for FY2023 expected ~80%; 375 Core Accounts (+13% YoY); 116 direct sales reps.","CEO Karen Zaderej to retire by Jan 2025; Board will search for successor; she will consult for 9 months after transition.","BLA submission for Avance Nerve Graft on track for H1 2024; Axoguard HA+ and Avive+ product rollouts planned.","Avance Nerve Graft surpassed 100,000 implants since launch; strong commercial execution cited."],"urls":{"canonical":"https://secwatch.observer/filing/0000805928-24-000005","json":"https://secwatch.observer/filing/0000805928-24-000005.json","markdown":"https://secwatch.observer/filing/0000805928-24-000005.md","text":"https://secwatch.observer/filing/0000805928-24-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000005/0000805928-24-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000005/axgn-20240104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:23:53.346060+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6029c5a173059083aab8bfdd4c96c9f50357b8e4","claim":"Axogen, Inc. reported full year 2023 results: revenue $158.8 million. Guidance reaffirmed.","evidence_excerpt":"Full-year 2023 revenue is expected to be approximately $158.8 million, which represents a 15% increase over the full-year of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000005/0000805928-24-000005-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$158.8 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"a98c10abdf904ffd7ab629e5ebd471292e180224","claim":"Axogen, Inc. reported fourth quarter 2023 results: revenue $42.7 million.","evidence_excerpt":"Fourth quarter revenue is expected to be approximately $42.7 million, which represents an 18% increase over the fourth-quarter of 2022 driven by solid performance across the product portfolio.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000005/0000805928-24-000005-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter 2023"},{"label":"Revenue","value":"$42.7 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"75a3a948cb","claim":"Karen Zaderej departed as Chief Executive Officer and President at Axogen, Inc..","evidence_excerpt":"Retirement of Karen Zaderej Karen Zaderej, the Chief Executive Officer (the “CEO”) and President of the Company informed the Company of her intention to retire in January 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000005/0000805928-24-000005-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retire"},{"label":"Role","value":"Chief Executive Officer and President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}